Medicines Discovery Catapult (MDC) and Crown Bioscience have announced a collaboration to deliver an integrated translational biology platform for companies developing radiopharmaceuticals.   The global collaboration between MDC and Crown Bioscience will support companies across the radiopharmaceutical pipeline, whether they are advancing radiotherapeutics, exploring new isotopes, or optimising targeting agents.  The companies will combine their expertise […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!